|Last Updated: June 16, 2021 @ 9:13 am|
|Stability:||Ambient: 2 Day(s); Refrigerated: 5 Day(s); Frozen: 3 Month(s); Incubated: Unacceptable|
|Interpretive Data:||General Reference Range : 0-25.0 U/mL|
The Roche e601 CA 15-3 electrochemiluminescent immunoassay is used. Results obtained with different methods or kits cannot be used interchangeably. The CA 15-3 assay is used to aid in the management of Stage II and III breast cancer patients. Serial testing for patient CA 15-3 assay values should be used in conjunction with other clinical methods for monitoring breast cancer. Patients with confirmed breast carcinoma frequently have CA 15-3 assay values in the same range as healthy individuals. Elevations may be observed in patients with nonmalignant disease. For these reasons, a CA 15-3 assay value, regardless of level, should not be interpreted as absolute evidence of the presence or absence of malignant disease.
Biotin in specimens taken from patients on high-dose biotin therapy or supplements may intefere with this test and cause inaccurate test results. It is recommended that for patients receiving therapy with high biotin doses (> 5 mg/day), no laboratory test specimen should be collected until at least 8 hours after the last biotin administration.
It is preferable to locate tests on the website and not rely on printed test information, which may soon be out of date.
Updated test information can only be guaranteed by using this website.